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KAJIAN KEBERKESANAN DAN KESELAMATAN DALAM 
PENGGUNAAN ANTIBIOTIK-ANTIBIOTIK BAGI PESAKIT-PESAKIT 
NEUTROPENIA FEBRIL YANG MENGALAMI TUMOR PEPEJAL DAN 
HEMATOLOGI DI HOSPITAL PAKAR RAJA FAHAD, SAUDI ARABIA 
 
ABSTRAK 
 
                 Neutropenia adalah faktor pendorong bagi pesakit-pesakit kanser 
mengalami komplikasi dan jangkitan-jangkitan teruk terutamanya patogen-patogen 
gram negatif dan positif. Pengetahuan tentang isolat-isolat bakteria yang 
menyebabkan neutropenia febril adalah sangat penting bagi  memulakan terapi 
antibiotik empirik yang dianggap sebagai suatu kecemasan perubatan di dalam 
pesakit-pesakit berisiko tinggi.Justeru itu, objektif utama kajian ini adalah untuk 
menilai keberkesanan dan keselamatan berkaitan dengan terapi antibiotik yang 
diberikan secara tunggal dan gabungan dalam pesakit neutropenia febril yang 
mengalami kanser pepejal dan hematologi.Suatu kajian eksploratori dan deskriptif 
telah dilakukan secara retrospektif dalam kalangan pesakit-pesakit dewasa (umur > 
16 tahun) neutropenia febril yang mengalami kanser pepejal dan hematologi, 
dimasukkan antara Mei 2008 dan Mei 2013 di Hospital Pakar Raja Fahad, Damman, 
Saudi Arabia. Daripada sejumlah 1748, hanya 258  pesakit-pesakit saja layak terlibat 
dalam kajian ini. Malignansi-malignansi terbanyak merangkumi 51.16% (132/258) 
hematologi dan 48.84% (126/258). pepejal. Sejumlah 138 isolat-isolat bakteria 
dikenalpasti dalam 106 jankitan-jangkitan yang terbukti secara mikrobiologi di 
dalam pesakit-pesakit neutropenia febril. Telah didapati bahawa prevalens patogen-
patogen gram negatif adalah 65.94% (91/138), manakala  34.06% (47/138) adalah 
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gram-positif.. Telah diperhatikan bahawa terdapat kadar tinggi bagi ESBL-ESBL 
kalangan Escherichia coli (38%) dan Klebsiella pneumoniae (22.22%) serta 
meningkatnya rintangan imipenem-cilastatin kalangan Pseudomonas aeruginosa 
(18.84%);manakala kadar MRSA adalah 28.72%. Daripada sejumlah 258, 96 
pesakit-pesakit telah di rawat secara terapi tunggal dengan piperacillin-
tazobactam(PT), vancomycin (VM) dan aminoglikosida (AG) telah ditambah pada 
terapi awal PT dan IC dalam 117 pesakit-pesakit. Terapi dalam kalangan 45 pesakit-
pesakit telah diubahsuai. Kadar respons terapi tunggal PT adalah lebih tinggi dalam 
kalangan pesakit-pesakit berumur antara 51-92 tahun (P=0.041) serta mereka yang 
mengalami neutropenia aruhan kemoterapi (P=0.026) setelah 12 hari menerima 
administrasi kemoterapi berbanding dengan kadar respons pada terapi-terapi PT+AG 
dan  PT+VM. Dalam malignansi-malignansi tumor pepejal, keabnormalan klinikal 
yang signifikan, seperti alkalina fosfatas, adalah tinggi  dalam kalangan pesakit-
pesakit yang dirawat secara terapi tunggal PT (P=0.016) berbanding dengan terapi 
PT+VM.  Peningkatan dalam tekanan darah (P=0.005), pengurangan paras 
hemoglobin  (P=0.006) dan pengurangan dalam pengiraan sel-sel darah putih 
(P=0.032) telah diperhatikan dalam pesakit-pesakit yang dirawat dengan terapi 
gabungan (PT + VM dan PT + AG).Kesimpulannya, penemuan penyelidikan ini 
telah mengambarkan bahawa prevalens organisme-organisme gram-negatif serta 
tapak-tapak isolasinya adalah sejajar dengan kajian-kajian antarabangsa. Sebaliknya, 
terdapat perbezaan dalam corak spektrum bakteria dan suseptibiliti. Seterusnya, 
kajian ini telah memperlihatkan bahawa tekanan darah meningkat dan paras 
hemoglobin serta pengiraan sel-sel darah putih telah berkurangan apabila VM atau 
AG ditambahkan pada terapi awal PT. Berlandaskan pada epidemiologi dan 
antibiogram-antibiogram tempatan, kami mencadangkan tambahan VM dan AG pada 
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terapi piawai apabila berdepan dengan jangkitan-jangkitan bakteria Gram-positif dan 
Gram-negatif yang rintang. 
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A STUDY ON EFFECTIVENESS AND SAFETY USE OF ANTIBIOTICS IN 
FEBRILE NEUTROPENIC PATIENTS WITH SOLID TUMOR AND 
HEMATOLOGICAL MALIGNANCIES IN KING FAHAD SPECIALIST 
HOSPITAL, SAUDI ARABIA 
 
ABSTRACT 
 
                   Neutropenia is a predisposing factor of serious complications and 
potentially life-threatening infections in patients with malignancies, particularly 
Gram-negative and Gram-positive infections. The local spectrum and sensitivity of 
bacterial isolates causing febrile neutropenia should be identified because facilitating 
appropriate empirical antibiotic therapies is considered as a medical emergency for 
these high-risk patients. Therefore, this study mainly aimed to evaluate the 
effectiveness and safety associated with single and combined antibiotic therapies for 
febrile neutropenic patients with solid tumor and hematological malignancies.An 
exploratory and descriptive study was conducted retrospectively among adult (age > 
16 years) febrile neutropenic patients with solid tumor and hematological 
malignancies admitted between May 2008 and May 2013 at the King Fahad 
Specialist Hospital, Dammam, Saudi Arabia. Of 1,748 patients, 258 were eligible to 
be included in the study. The majority of malignancies affecting 51.16% (132/258) 
of the patients was hematological. The remaining 48.84% (126/258) of the patients 
manifested solid tumor malignancies. A total of 138 bacterial isolates were identified 
in 106 microbiologically documented infections in the febrile neutropenic patients. 
The overall prevalence of Gram-negative infections was 65.94% (91/138). By 
contrast, the overall prevalence of Gram-positive infections was 34.06% (47/138). 
The rates of extended-spectrum beta-lactamase production among Escherichia coli 
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(38%) and Klebsiella pneumonia (22.22%) were high. The resistance to imipenem–
cilastatin (IC) treatment of Pseudomonas aeruginosa (18.84%) increased. The rate of 
occurrence of methicillin-resistant Staphylococcus aureus was 28.72%. Of the 258 
patients, 96 were treated with piperacillin–tazobactam (PT) monotherapy. 
Vancomycin (VM) and aminoglycosides (AG) were added to the initial PT and IC 
therapy for 117 patients. The therapy for 45 patients was modified. The response 
rates to PT therapy of the patients aged between 51 and 92 years (P=0.041) and those 
who developed chemotherapy-induced neutropenia (P=0.026) after 12 days of 
chemotherapy administration were higher than their corresponding response rates to 
PT + AG and PT + VM therapies. In solid tumor malignancies, clinically significant 
abnormalities, such as alkaline phosphatase, were higher in the patients treated with 
PT monotherapy (P=0.016) than in the patients subjected to PT + VM therapy. 
Increased blood pressure (P=0.005), decreased hemoglobin levels (P=0.006) and 
decreased white blood cell counts (P=0.032) were observed in the patients treated 
with dual therapies (PT + VM and PT + AG). In conclusion, the prevalence of Gram-
negative bacteria and the isolation sites of these microorganisms were similar to 
those described in other international studies. Conversely, different trends were 
observed in terms of bacterial spectrum and susceptibility patterns. Our results 
confirmed that PT is effective and safe for monotherapy. Our study further revealed 
that blood pressure increased and hemoglobin levels and white blood cell counts 
decreased when VM or AG was added to the initial PT therapy. On the basis of local 
epidemiology and antibiograms, we recommend the addition of VM and AG to 
standard therapy when resistant Gram-positive and Gram-negative bacterial 
infections are encountered.  
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CHAPTER 1  
 INTRODUCTION 
1.1 Historical background of neutropenia 
 Neutropenia is a hematological disorder characterized by an abnormal decrease in 
the absolute number of neutrophils or an expected decrease to ˂500 cells/mm3 in the 
next 48 h (Bow, 2005; Freifeld et al., 2011; National Comprehensive Cancer, 2013). 
Neutrophils are white blood cells (WBCs) produced in the bone marrow and they 
account for approximately 60% of blood. These cells serve as primary defense 
against infections by destroying pathogens in blood (Frey, 1999; Simmons). These 
WBCs are also the first cellular components that function in inflammatory and 
infectious responses (Crawford, Dale, & Lyman, 2004). In patients with 
malignancies, neutropenia is a predisposing factor of serious complications and 
potentially life-threatening infections caused by Gram-negative and Gram-positive 
pathogens. In chronic neutropenia, a rapid decrease in neutrophil count indicates a 
high risk of acquiring a life-threatening infection (Glauser, 2000; Link et al., 2003). 
If neutropenia lasts less than 7–10 days, the risk of infection is low. By contrast, the 
risk of infection is high if the condition exceeds 10 days. Therefore, the risk of 
infection and mortality correlate with the degree of severity, the duration of 
neutropenia and the presence of fever (Gerald P. Bodey, Rodriguez, Chang, & 
Narboni, 1978; Caggiano, Weiss, Rickert, & Linde‐Zwirble, 2005). 
Neutropenia is categorized as mild, moderate or severe (Baehner, 2003). This 
condition is also classified by the Severe Chronic Neutropenia International Registry 
into two forms: congenital, which occurs by birth, and acquired, which manifests at 
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any time throughout life. Congenital or Kostmann neutropenia is further defined as 
maturation arrest in the early stages of neutrophil development in the bone marrow. 
Autoimmune neutropenia is a condition involving the destruction of the body’s own 
blood neutrophils by neutrophil-specific antibodies (David C Dale et al., 2003). The 
concentration of neutrophils in blood is influenced by age, genetics and 
environmental factors. In certain geographical areas, some populations yield 
different neutrophil blood concentrations. For instance, populations of African 
descent possess lower normal neutrophil blood concentrations than those of 
European descent (Lichtman, 2006). 
1.2 Causes of neutropenia  
Several risk factors influence the onset of neutropenia. The common risk factors of 
neutropenia are hematological disorders, autoimmune disease, drug reactions, 
chemotherapy and radiation therapy. The general risk factors of the development of 
severe neutropenia are old age and performance status because mature neutrophil 
production is lower in old population than in young individuals. Furthermore, the 
incidence of neutropenia is higher in females than in males (Crawford et al., 2004; 
B. A. Rasool Hassan, Yusoff, & Othman, 2010; Lyman, Lyman, & Agboola, 2005). 
The presence of comorbid conditions, such as liver, renal and cardiovascular 
diseases, also increases the risk of developing neutropenia. Likewise, sepsis, 
pneumonia, hypertension and chronic pulmonary disease exacerbate neutropenic 
complications. Other indicators of neutropenia include decreased white blood cell 
counts and low hemoglobin and serum albumin concentrations (Crawford et al., 
2004; B. A. Rasool Hassan et al., 2010; Lyman et al., 2005). 
3 
 
Neutropenia is often diagnosed in patients with hematological malignancies. Under 
this condition, neutrophil production decreases as bone marrow and hematopoietic 
stem cells are destroyed and thus possibly results in neutropenia. These patients may 
also be at risk of infectious complications and require thorough examination (Boxer, 
2012; B. A. Rasool Hassan et al., 2010).  
Cytotoxic chemotherapy regimens and radiation therapy predictably suppress the 
hematopoietic system and destroy the bone marrow; these conditions decrease 
neutrophil counts and thus increase the susceptibility to infection of patients 
(Crawford et al., 2004; B. A. Rasool Hassan et al., 2010; Lyman et al., 2005; 
Takenaka et al., 2013). High doses of cyclophosphamide, etoposide and 
anthracyclines are significant predictors of severe neutropenia (Lyman et al., 2005).  
Other drugs, such as clozapine, antithyroid drugs, sulfasalazine, ticlopidine, 
angiotensin converting enzyme inhibitors, H2 blockers, nonsteroidal anti-
inflammatory drugs and antiarrhythmic drugs (e.g., tocainide, procainamide and 
dapsone), are also predictors of severe neutropenia. Drugs, such as colchicine, 
azathioprine, ganciclovir and methotrexate, suppress bone marrow functions 
(Baehner, 2003). Chlorpromazine and allopurinol, which are diuretics, also cause 
neutropenia (B. A. Rasool Hassan et al., 2010). 
1.3 Pathophysiology of neutropenia  
Neutrophils are the most abundant type of WBCs; they constitute an essential part of 
the innate immune system and first line of defense. Neutrophils are also known as 
granulocytes or polymorphonuclear segmented cells and they account for 60%–70% 
of circulating absolute neutrophil count (Bhatt & Saleem, 2004). In host defense, 
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neutrophils rapidly respond to invading microorganisms (Witko-Sarsat, Rieu, 
Descamps-Latscha, Lesavre, & Halbwachs-Mecarelli, 2000).  
In the bone marrow, mature neutrophils are produced by precursors in 10–14 days. 
These cells then enter the blood pool without re-entry into the marrow. The life span 
of neutrophils is very short (i.e., only 4–8 h); thus, the bone marrow must 
continuously produce neutrophils. These neutrophils leave the blood pool and 
subsequently enter tissues or infected sites, where they perform cellular action or 
die. Chemotherapy triggers bone marrow suppression and stem cell destruction, 
which decrease neutrophil production. Mature cells die and remain unreplaced; as a 
consequence, the body’s ability to fight infection weakens (D. C. Dale, 2005; 
Goodwin & Braden; O’Leary, 2010).  
1.4 Etiology of fever, infection and microbial spectrum  
1.4.1 Etiology of fever in neutropenia  
Fever may be the most common manifestation of infection in a neutropenic patient. 
Cancer patients with febrile neutropenia present with fever manifested by single oral 
temperature measurement of >38.3 °C (101 ° F) or a temperature of >38.0 °C 
(100.4 °F) sustained for 1 h (Bošnjak, 2004; Bow, 2005; De Naurois, Novitzky-
Basso, Gill, Marti, Cullen, & Roila, 2010; Freifeld et al., 2011; National 
Comprehensive Cancer, 2013).  
Fever often occurs in 48% of episodes when the neutrophil count decreases below 
100 cells/mm
3
 and 70% of febrile episodes manifest when the neutrophil count is 
<500 cells/mm
3
. Only 10% of febrile episodes are observed in patients whose 
neutrophil count is >2000 cells/mm
3
. Depending on infection, the proportion of 
fever varies from 49% to 68% (Gerald P. Bodey et al., 1978). 
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Approximately 10%–50% of patients with solid tumor suffer from fever, whereas 
80% of neutropenic patients with hematological malignancies develop fever after 7–
12 days of chemotherapy regimen (Klastersky, 2004; Legrand, Max, Schlemmer, 
Azoulay, & Gachot, 2011). The 20%–55% of neutropenic patients manifest fever 
because of bacterial infections after they undergo chemotherapy (Ammann, Hirt, 
Lüthy, & Aebi, 2003). 
In addition to bacterial and fungal infectious agents, noninfectious agents, such as 
blood transfusion, some drugs (azathioprine, allopurinal, gancyclovir, methotrexate 
and procainamide) and granulocyte colony-stimulating factors (GCS-F), trigger 
fever in neutropenic patients. Although bacterial infection rapidly develops in 
neutropenic cancer patients, signs of inflammatory response are rarely observed. 
Thus, history of associated diseases, currently used drugs, latest chemotherapy and 
family background of patients should be thoroughly evaluated. Physical examination 
involving infection site inspection and bone marrow biopsy should also be 
conducted; infection sites for inspection include the oral mucosa, sinuses, chest, ear, 
skin, nails, anal area, vaginal area and catheter insertion sites (Lee et al., 2011). 
1.4.2 Epidemiology of infection in neutropenia 
The incidence of infection is 14% in patients with neutrophil counts below 500–
1000 cells/mm
3
. WBC count rapidly decreases as the duration of neutropenia 
prolongs (Kanneth V. I. Rolston, 2009). 
1.4.2 (a) Classification of Infections 
Febrile episodes are classified into three groups. 
1.4.2.1(a)i Microbiologically Defined Infections (MDI): These episodes involve 
fever and microbial isolation (Kanneth V. I. Rolston, 2009).  
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1.4.2.1(b)ii Clinically Defined Infections (CDI): These episodes involve a defined 
site of infection (pneumonia, enterocolitis or cellulite) but lack microbiological 
confirmation (Kanneth V. I. Rolston, 2009).  
1.4.2.1(c)iii Fever of Unknown Origin (FUO): These episodes are characterized by 
fever without clinical causes or microbiological documentation of infection. These 
episodes are also referred to as ―episodes of unexplained fever‖ (Kanneth V. I. 
Rolston, 2009). 
1.4.2(b) Bacterial infection 
Bacterial infections generally occur in the initial phases of febrile neutropenia; by 
contrast, fungal infections frequently occur in prolonged and severe neutropenia 
(Gabay & Tanzy, 2010; Kenneth V. I. Rolston & Bodey, 2011). More than 60% of 
neutropenic patients who become febrile are at risk of infection (Billote, Mendoza, 
& Baylon, 1997; Gençer, Salepçi, & Özer, 2003). Bacteremia accounts for 35% of 
hematological malignancies and 20% of solid tumor malignancies. A high mortality 
rate is also associated with polymicrobial infections (Viscoli, Varnier, & Machetti, 
2005).  
1.4.2(c) Fungal infections 
Approximately 20% of patients with neutropenia suffer from invasive fungal 
infections (Eltahawy, 2003). Fungal infections usually occur after a long duration of 
broad-spectrum antibiotic therapy. Common fungal infections and serious 
complications in neutropenic patients are caused by Aspergillus species and Candida 
species, such as C. albicans, C. tropicalis and C. glabrata (Eltahawy, 2003). Fungal 
infections may become a primary concern for patients with prolonged neutropenia 
(B. A. Rasool Hassan et al., 2010). 
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1.4.2(d) Viral infections 
Viral infections are common in patients with impaired cellular immunity but not in 
patients with neutropenia (Kenneth V. I. Rolston & Bodey, 2011). Viral infections 
mostly occur in bone marrow recipients. The most common viruses are herpes 
simplex, cytomegalovirus and varicella zoster (B. A. Rasool Hassan et al., 2010). 
1.4.2(e) Site of infection 
The common infection sites in febrile neutropenic malignant patients are 
bloodstream, respiratory tract, urinary tract, skin/skin structures and gastrointestinal 
tract (Viscoli et al, 2005; Rolston, 2009; Nesher et al., 2014). A study conducted by 
the University of Texas M. D. Anderson Cancer Center has revealed that tissue-
based infections, such as pneumonia, urinary tract infections and soft tissue 
infections caused by Gram-negative organisms, are more common than 
bloodstream-based infections (Sipsas, Bodey, & Kontoyiannis, 2005).  
1.4.3 Bacterial spectrum in neutropenia   
Bacterial infection is a primary cause of fever in 25% of neutropenic cancer patients; 
conversely, fungal infections cause fever in 5% of neutropenic patients (Collin, 
Leather, Wingard, & Ramphal, 2001). Infections in febrile neutropenia are caused 
by Gram-positive or Gram-negative organisms, fungi or even viruses (Bal & Gould, 
2007; B. A. Rasool Hassan et al., 2010).  
Gram-negative organisms were predominant in the 1960s until the 1980s. 
Approximately 60%–80% of these infections were microbiologically documented. 
The most predominant organisms are Gram-negative bacteria; most of these bacteria 
are β-lactamase producers, such as Escherichia coli, Pseudomonas aeruginosa and 
Klebsiella spp. P. aeruginosa and Staphylococcus aureus infections yield high 
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mortality rates (Eltahawy, 2003; Kanamaru & Tatsumi, 2004; Okereke & Dudley, 
1998; Zinner, 1999).  
In the late 1980s, the multicenter trials conducted by the European Organization for 
Research and Treatment of Cancer–International Antimicrobial Therapy 
Cooperative Group (EORTC–IATCG) showed that the rate of Gram-positive 
infections steadily increased to 60%–70%. Coagulase-negative staphylococci and S. 
aureus are predominant bacterial agents of infections. Overall, the EORTC studies 
from 1973 to 1993 demonstrated a shift from Gram-negative organisms to Gram-
positive organisms in microbiologically documented infections in febrile 
neutropenic cancer patients (Eltahawy, 2003; Glasmacher et al., 2005; Kanamaru & 
Tatsumi, 2004; Swati, Gita, Sujata, Farah, & Preeti, 2010; Zinner, 1999). The same 
trials revealed that the rate of Gram-negative infections decreased from 71% to 31% 
(Swati et al., 2010).  
An EORTC review reported that the incidence rates of Gram-negative and Gram-
positive infections between 1993 and 2000 were similar (12% and 13%, 
respectively), with a significant increase in the rate of Gram-negative infections 
(Glasmacher et al., 2005). 
However, the reason for this change in the spectrum of pathogens remains unclear 
(Viscoli, 1998). Studies have assumed that the shift from Gram-negative infections 
to Gram-positive infections is due to long-term indwelling catheters, aggressive 
chemotherapy, continuous evolution of antibiotic use and changes in clinical and 
local antibiotic resistance (Ramphal, 2004; Viscoli et al., 2005).  
The spectrum of infectious pathogens has further changed. Studies in the US and 
Europe have reported the re-emergence of Gram-negative bacteria in neutropenic 
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cancer patients (Gençer et al., 2003; Ramphal, 2004; Swati et al., 2010; M. Walwyn, 
A. Nicholson, M. G. Lee, G. Wharfe, & M. A. Frankson, 2010). Gençer et al. (2003) 
isolated 74.4% of Gram-negative organisms from neutropenic cancer patients and 
found that E. coli (31%) is the most predominant, followed by K. pneumoniae 
(18%), P. aeruginosa (13%) and Streptococcus pneumoniae (13%). 
El Saghir et al. (1989) revealed that Gram-negative and Gram-positive isolates 
respectively account for 51% and 26% of infections in acute leukemia in Riyadh, 
Saudi Arabia. Kanafani et al. (2007) performed a study in the American University 
of Beirut Medical Center between 2001 and 2003 in Lebanon and reported that 
Gram-negative and Gram-positive organisms are responsible for 78.8% and 33.3% 
of infections, respectively. Baskaran et al. (2007) conducted a retrospective study at 
a university medical center in Malaysia and found that 60.3% of infections are 
caused by Gram-negative bacteria. 
1.5 General approach to treatment 
1.5.1 Granulocyte-colony stimulating factor (G-CSF)  
In the 1960s, the discovery of colony-stimulating or myeloid growth factors was 
considered as a great achievement in the history of hematology and development of 
medical oncology practice. G-CSF stimulates the proliferation of neutrophils and 
accelerates their transport from the bone marrow to the blood pool. The 
development and release of neutrophils occur in three sites: in the bone marrow 
where cells develop from stem cells to mature, in the blood where neutrophils flow 
along with red blood cells and in infected tissues where neutrophils kill bacteria. The 
normal time for neutrophil production from the bone marrow to the blood pool is 6 
days. D. C. Dale (2001) reported a 50% reduction in time (i.e., about 3–6 days) of 
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neutrophil maturation and release. Crawford et al. (2004) conducted randomized 
controlled trials and demonstrated that G-CSF considerably accelerates neutrophil 
recovery after chemotherapy (Aapro, Crawford, & Kamioner, 2010; Gerlier et al., 
2010).  
The guidelines of the American Society of Clinical Oncology (ASCO), EORTC–
IATG, European Society for Medical Oncology (ESMO) and the National 
Comprehensive Cancer Network (NCCN version 1.2013) for the use of G-CSF are 
based on risk factors. These factors include the type of chemotherapy and patient-
related factors, such as age, performance status and comorbidities. Febrile 
neutropenia is categorized into three groups on the basis of risk factors, namely, low 
risk (˂10%), intermediate risk (˂10%–20%) and high risk (>20%). These guidelines 
recommend the use of G-CSF for patients with a high risk (>20%) of febrile 
neutropenia (Gerlier et al., 2010).  
1.5.2 Strategies of antimicrobial therapy 
In the early 1960s, the incidence of neutropenia was accompanied by potent factors, 
such as degree and duration of neutropenia and overall risk of infection. Virulent 
Gram-negative organisms predominantly cause death and sepsis. However, a limited 
number of antibiotics were available to treat infections during that time. 
Aminoglycosides (AGs) were introduced in the 1970s; carbapenem, monobactams 
and quinolones were made available in the 1980s (Hathorn & Lyke, 1997; Sipsas et 
al., 2005).  
With the development of broad-spectrum β-lactam antibiotics 10 years ago, the 
effectivity of broad-spectrum antibiotic monotherapy in the treatment of febrile 
neutropenic patients has been extensively investigated. In theory, monotherapy 
provides several advantages over combination therapy; these advantages are reduced 
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toxicity and ease of administration. Nevertheless, monotherapy and combination 
therapy are characterized by several drawbacks, including inconsistencies in 
objectives and definitions of success and failure. Researchers have yet to provide 
evidence that supports monotherapy as the gold standard of empirical antibiotic 
therapy (Viscoli, 1998). 
 Combination therapy is the optimum treatment approach for febrile neutropenic 
patients. The combination of antibiotic regimens synergistically affects Gram-
negative organisms. However, combination therapy provides several disadvantages, 
such as high cost and unpredictable pharmacodynamic antibiotic behavior (Viscoli, 
1998). 
Appropriate antimicrobial stewardship strategies are required to reduce the risk and 
consequences of febrile neutropenia (Lyman et al., 2010). However, 
recommendations for the initial empirical antibiotic therapy for febrile neutropenia 
can be provided if clinicians are aware of local bacterial spectrum, susceptibility 
patterns and individual clinical situations (Hathorn & Lyke, 1997; Klastersky, 
2004). No single antibiotic regimen is optimal. As such, changes in bacterial 
spectrum, resistance patterns and new therapeutic agent availability have led to the 
development of new options (K. V. Rolston, 1999). 
The Infectious Disease Society of America (IDSA), ASCO, NCCN, Infectious 
Diseases Working Party of the German Society of Hematology and Oncology and 
Chemotherapy Society of Spain (SEQ) established clinical practice guidelines for 
the empirical initial antibiotic therapy (Table 1.1) for febrile neutropenic patients 
(Glasmacher et al., 2005; Lyman & Rolston, 2010; Sipsas et al., 2005). 
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Table 1.1 Recommendations for the empirical initial antibiotic therapy for 
febrile neutropenia 
 
Guidelines Monotherapy Combination Therapy 
IDSA (Infectious 
Disease Society of 
America) 
Ceftazidime 
Piperacillin–Tazobactam/Ticarcillin/Clavulanate + 
Aminoglycoside 
Cefepime Aminoglycoside + Cefepime–Ceftazidime 
IC Aminoglycoside + Imipenem–Cilastatin 
Meropenem Aminoglycoside + Meropenem 
PT   
NCCN (National 
Comprehensive Cancer 
Network) 
Ceftazidime Aminoglycoside + Anti-pseudomonal penicillin 
Cefepime Aminoglycoside + Extended-spectrum cephalosporin 
IC Ciprofloxacin + Anti-pseudomonal penicillin 
Meropenem Double β-Lactam 
IHO (Infectious 
Diseases Working Party 
of the German Society 
of Hematology and 
Oncology) 
PT Aminoglycoside + Acylaminopenicillin 
Ceftazidime 
Aminoglycoside + Third- or fourth-generation 
cephalosporin 
Cefepime 
IC 
Meropenem 
SEQ (Chemotherapy 
Society of Spain) 
Cefepime 
Not recommended for routine use Meropenem 
PT 
IC: Imipenem–cilastatin, PT: Piperacillin–tazobactam 
1.6  Outcome measurements 
1.6.1 Evaluation of response  
Primary outcome included treatment success without modification or addition of 
other antibiotics to initial treatment regimen within 72 h of therapy. The response to 
therapy was assessed after 72 h of therapy (Frank, Mutter, Schmidt‐Eisenlohr, & 
Daschner, 2003; Freifeld et al., 2011; Harter et al., 2006; Oztoprak et al., 2010; 
Rossini et al., 2005). 
1.6.2 Effectiveness of therapy 
The effectiveness of therapy was defined on the basis of the following endpoints: (1) 
complete resolution of fever (reduction in temperature to <38 °C measured orally 
and sustained for 48 h); (2) complete disappearance of clinical signs and symptoms 
of infection (clinical deterioration and progression of presumed infection); and (3) 
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bacteriological response of eradication of infectious organisms without changes in 
the initially assigned therapy (Frank et al., 2003; Freifeld et al., 2011; Harter et al., 
2006; Oztoprak et al., 2010; Rossini et al., 2005). 
1.6.3 Failure of therapy  
The failure of therapy was evaluated on the basis of the following endpoints: (1) 
when antimicrobial therapy was modified by adding other antibiotics or 
discontinuing the initial empirical therapy and initiating other new antibiotics for 72 
h of treatment; (2) persistent fever in a patient with signs of clinical deterioration, 
microbiological evidence and clinical progression of the presumed infection or 
adverse event associated with the antibiotic regimen; and (3) deaths occurring within 
72 h of treatment (Freifeld et al., 2011; Harter et al., 2006; Hess, Böhme, Rey, & 
Senn, 1998; Oztoprak et al., 2010).  
1.6.4 Toxicities 
The safety of therapy was evaluated by monitoring laboratory values. 
Nephrotoxicity and hepatotoxicity, which are characterized by an increase in serum 
creatinine, transaminases, bilirubin or alkaline phosphatase by at least twice the 
upper normal limit, were examined through laboratory analysis (Harter et al., 2006; 
Raad, Abi‐Said, Rolston, Karl, & Bodey, 1998). Hypokalemia is defined as an 
increase in serum potassium level of >10 mmol below the lower limit of the normal 
range (Ariffin et al., 2001).  
1.6.5 Overall improvement  
Overall improvement was assessed after 7 days (Frank et al., 2003; Freifeld et al., 
2011; Harter et al., 2006; Oztoprak et al., 2010; Rossini et al., 2005). 
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1.7 Global incidence of neutropenia  
The risk of infection is at its maximum when neutrophil count is <500 cells/mm
3
 
(Hsieh, Everhart, Byrd-Holt, Tisdale, & Rodgers, 2007). The normal level of 
neutrophils in human blood varies with age, race and ethnicity (Frey, 1999). Grann 
et al. (2008) surveyed 261 populations of six ethnic groups from the Caribbean and 
the US and evaluated the association between the country of origin and the normal 
WBC and ANC levels. This survey revealed that populations of African and 
Caribbean descents more likely possess lower WBC counts and ANCs than those of 
Caucasians and Dominicans. According to the National Health and Nutritional 
Examination Survey from 1999 to 2004, the prevalence of neutropenia varies with 
age, gender and ethnicity. The prevalence rates of neutropenia are 4.5%, 0.79% and 
0.38% in African–American, Caucasian and Mexican–American participants, 
respectively. Among these ethnic groups, 6.65% of African–American males and 
3.57% of African–American females are likely neutropenic; by contrast, 0.90% of 
Caucasian males and 0.59% of Caucasian females and 0.57% of Mexican–American 
males and 0.39% of Mexican–American females are neutropenic (Hsieh et al., 
2007).  
The reference range of neutrophil count in Arabs has not been established. Studies 
have proposed that the Arab population possesses lower neutrophil counts than other 
ethnic groups do (Europeans and Mexicans). These Arab populations live in tribes 
and practice endogamy; thus, genetic conditions are altered (Denic et al., 2009). 
Denic and Nicholls (2011) conducted a survey at Al Ain Hospital, United Arab 
Emirates and found that the mean neutrophil count in Arabs is lower than that in 
European populations. In the past three decades, benign neutropenia was commonly 
observed among Jordanians, Kuwaitis and Palestinians. More than 30% of the 
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Omani Arab population presents abnormal neutrophil levels (Al-Ankoodi & 
Rawther, 2004). Al-Qahtani (2008) found that 90.7% of Saudi Arabian populations 
exhibited mild neutropenia and 9.3% presented with moderate neutropenia between 
1995 and 2006 at the King Khaled University Hospital, Saudi Arabia.   
1.8 Conceptual framework  
Febrile neutropenia is induced by combination therapy and monotherapy of 
cytotoxic drugs in cancer patients. The intensity of chemotherapeutic agents is a risk 
factor of neutropenia development (Lyman et al., 2005; Lyman & Rolston, 2010). 
Neutropenia can be complicated by bacterial infections. Bacterial etiology has 
shifted from Gram-positive organisms to Gram-negative organisms (Baskaran, Gan, 
Adeeba, & Sam, 2007; Burney, Siddiqui, Farooqui, & Khurshid, 1998; Eltahawy, 
2003; Bassam Abdul Rasool Hassan, Yusoff, & Othman, 2011; Kanafani et al., 
2007; D Yadegarynia, Tarrand, Raad, & Rolston, 2003). Regional and climatic 
conditions also influence the changes in bacterial etiology (Hathorn & Lyke, 1997; 
Wingard, 2011). Considering these findings, we provide a precise guide on the 
selection of a first-line empirical antimicrobial therapy in the management of 
infections in febrile neutropenic episodes. This study also emphasizes the optimal 
selection of combination therapy for the broad-spectrum coverage and synergistic 
effect of antibiotics. 
This study aims to survey the dependent variables of the effectiveness and safety of 
antibiotic use in febrile neutropenic cancer patients. Despite the effectiveness of 
antibiotics, certain antibiotics are characterized by several drawbacks, such as 
nephrotoxicity and hepatotoxicity (Hathorn & Lyke, 1997). Our study also 
highlights the predictor variables of the effectiveness and toxicity of antibiotics in 
febrile neutropenic cancer patients.  
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Our conceptual framework is categorized as the initial development of febrile 
neutropenia after patients receive chemotherapeutic agents and manifest infection. 
This study is divided into the following three stages. Stage 1 and Figure 1.1 
summarize the development of neutropenia and selection of effectiveness, safety and 
outcome variables for the success of empirical monotherapy and combination 
antibiotic therapy in febrile neutropenia with solid tumor and hematological 
malignancies. Stage 2 and Figure 1.2 represent the assessment of the effectiveness, 
safety and outcome variables for the success of monotherapy or combination 
therapy. Stage 3 and Figure 1.3 present a comparison between monotherapy and 
combination antibiotic therapy in terms of success and failure of initial therapy. 
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Stage 1. Development of febrile neutropenia, evaluation of effectiveness and 
safety and outcome variable 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ALT: Alanine transaminase. ALP: Alkaline phosphatase. ANC: Absolute neutrophil count. ADR: Adverse drug reaction, 
BUN: Blood urea nitrogen. CDI: Clinically defined infection. FUO: Fever of unknown origin. GGT: Gamma glutamyl 
transferase. Hg: Hemoglobulin. K+: Potassium. MDI: Microbiologically defined infection. Mg: Magnesium. SrCr: Serum 
creatinine. 
Figure 1.1 Conceptual framework for the selection of monotherapy or combination 
therapy and its effectiveness, safety and other influencing variables 
Chemotherapy agents 
Develop neutropenia in less than 12 daysor more than 12 days and followed by 
infection 
Febrile neutropenia in solid and 
hematological malignancies Modification/ 
addition of any 
other antibiotics 
to initial therapy 
/clinical 
deterioration/ no 
eradication of 
bacteria/ADR is 
considered as 
therapeutic 
failure. 
Empirical administration of 
monotherapy or combination 
therapy antibiotics therapy 
Monitoring of the effect and toxicity 
of antibiotic therapy  
Evaluation after 72 h of therapy 
Monotherapy Combination therapy 
Outcome 
Safety variables Other variables Dependent variables 
Nephrotoxicity 
1. SrCr level 
2. SrCr clearance 
Hepatotoxicity 
1. Total bilirubin 
2. ALT 
3. ASP  
4. GGT 
 
1. Demographics 
2. Hg level 
3. Electrolyte Imbalance 
a. Mg 
b. K+ 
c. BUN 
 
 
 
1. Fever 
2. MDI 
3. CDI 
4. FUO 
5. ANC 
6. Outcome variables 
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Stage 2. Assessment of the effectiveness and safety of antibiotics in febrile 
neutropenic cancer patients 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ALT: Alanine transaminase. ASP: Alkaline phosphatase. BUN: Blood urea nitrogen. GGT: 
Gamma glutamyl transferase. K
+
: Potassium. SrCr: Serum creatinine. Mg: Magnesium. 
 
 
Figure 1.2 Assessments of initial antibiotic therapy in terms of effectiveness, 
safety and overall improvement 
Assessment of dependent 
variables 
Safety parameters Other variables Effectiveness parameters 
Nephrotoxicity 
Increase in normal 
range of: 
1. SrCr 
2. SrCr level 
Hepatotoxicity 
Increase in normal 
range of: 
1. Total bilirubin 
2. ALT 
3. ASP 
4. GGT 
 
Demographics 
1. Age 
2. Sex 
Electrolyte 
Imbalance 
1. Mg 
2. K+ 
3. BUN 
1. Defervescence 
of fever 
2. Microbial 
eradication 
3. Clinical cure 
 
Assessment of outcome variables 
 Duration of fever 
 Duration of neutropenia 
 Length of stay 
 
Overall 
Improvement 
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Stage 3 Comparison of monotherapy versus combination therapy in 
terms of effectiveness, safety, outcome variables and overall 
improvement 
 
 versus 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Logistic univariate and multivariate regression analyses of 
monotherapy versus combination therapy 
 
 
 
Monotherapy Combination therapy 
 
Univariate logistic regression 
analysis of the following 
variables: 
 Effectiveness 
 Safety 
 Outcome variables 
 Overall improvement 
 
Multivariate logistic 
regression analysis 
Predictor variables for the effectiveness and safety of 
antibiotics in febrile neutropenia. 
Selection of appropriate 
antibiotic therapy for the 
treatment of febrile neutropenic 
patients with hematological 
malignancies. 
 
Selection of appropriate 
antibiotic therapy for the 
treatment of febrile neutropenic 
patients with solid tumor 
malignancies. 
